Economic evaluations on use of aripiprazole for patients with schizophrenia: a systematic review (2018)
- USP affiliated author: HENRIQUE, IARA CAROLINA BARBOSA - FCF
- School: FCF
- Subjects: ESQUIZOFRENIA; REVISÃO SISTEMÁTICA
- Language: Inglês
- Abstract: INTRODUCTION: Schizophrenia is a serious mental disorder and is associated with substantial economic and social burden. Cost-effectiveness analyses are important in assessing differences in value between treatment options. However, there is lack of information on the reporting quality of economic evaluations, cost drivers, as well as updated data focused on aripiprazole - antipsychotic drug commonly prescribed for schizophrenia. OBJECTIVE: To elaborate a systematic review to evaluate the full economic evaluations on the use of aripiprazole in schizophrenia, to identify cost drivers and to critically evaluate the reporting quality of the studies. MATERIALS AND METHODS: A literature research was conducted in PubMed, NHS Economic Evaluation Database, CEA Registry, and LILACS databases until March 2018. This review included cost-effectiveness or cost-utility analyses based on decision models, published in English, Portuguese, or Spanish, which evaluated the costs and outcomes of aripiprazole in schizophrenia. The selection of studies, data extraction, and evaluation of the reporting quality of economic evaluations were carried out by two independent authors and the differences were solved by a third author. The reporting quality was evaluated by the CHEERS checklist. RESULTS: The literature search has identified 79 potential studies, from which 17 model-based economic evaluations fully met the eligibility criteria. Of these, 15 were industry-funded studies. A trend favoring olanzapine, lurasidone, and paliperidone could be observed, while aripiprazole was extensively described as a dominated alternative. In addition, 93% of the industry-funded studies presented favorable results to their sponsor; two of them being aripiprazole’s manufacturer. With regards to cost drivers, they were usually related to relapse rates/probabilities. The reporting quality ofthe economic analyses was poor, with most studies got around 12-13 points. CONCLUSION: No consistent conclusion on aripiprazole’s cost-effectiveness can be drawn due to due to the context-specific costs, conflicting parameters of effectiveness and safety, and criticism related to industry sponsorship. The most reliable finding that can indeed be drawn from this review were the cost drivers, which was usually related to relapse rates/probabilities, regardless of the study funding. Furthermore, the poor reporting quality of the economic studies requires improvement to ensure greater reliability of the findings
ABNTHENRIQUE, Iara Carolina Barbosa; AGUIAR, Patrícia Melo. Economic evaluations on use of aripiprazole for patients with schizophrenia: a systematic review. [S.l: s.n.], 2018.
APAHenrique, I. C. B., & Aguiar, P. M. (2018). Economic evaluations on use of aripiprazole for patients with schizophrenia: a systematic review. São Paulo.
NLMHenrique ICB, Aguiar PM. Economic evaluations on use of aripiprazole for patients with schizophrenia: a systematic review. 2018 ;
VancouverHenrique ICB, Aguiar PM. Economic evaluations on use of aripiprazole for patients with schizophrenia: a systematic review. 2018 ;
Download do texto completo
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas